

N-SN ong Term Care Facility Component—Annual Facility Survey

Safety	Network

Page 1 of 4					
*required for saving	Tracking #:				
Facility ID:	*Survey Year:				
State Provider #:					
Facility Characteristics					
*Ownership (check one):					
□ For profit □ Not for profit, including church	□ Government (not VA)	□ Veterans Affairs			
*Certification (check one):					
Dual Medicare/Medicaid Medicare only	Medicaid only	\Box State only			
*Affiliation (check one):	□ Independent, continuing	care retirement community			
☐ Multi-facility organization (chain) ☐ Hospital system, a	attached 🛛 🗌 Hospital syste	em, free-standing			
In the previous calendar year:					
*Average daily census:					
	e length of stay for short-stay				
*Total number of long-stay residents: Average	e length of stay for long-stay				
*Total number of new admissions:					
*Number of Beds: *Number of Pediatric Beds	(ane <21) [.]				
*Indicate which of the following primary service types are provid		av of this survey indicate			
the number of residents receiving those services (list only one s resident census on day of survey completion):					
Primary Service Type Se	ervice provided? Number	of residents			
a. Long-term general nursing:					
b. Long-term dementia:					
c. Skilled nursing/Short-term (subacute) rehabilitation:					
d. Long-term psychiatric (non dementia):					
e. Ventilator:					
f. Bariatric:					
g. Hospice/Palliative:					
h. Other:					
		Continued >>			
Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).					
Public reporting burden of this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0666). CDC 57.137 (Front) Rev 4 v8.5					



Long Term Care Facility Comp	onent—Annual Facility Survey
Facility Microbiology Laboratory Practices	
*1. Does your facility have its own laboratory that performs	s microbiology/antimicrobial susceptibility testing?
□ Yes □ No	
If No, where is your facility's antimicrobial susceptible	ility testing performed? (check one)
\Box Affiliated medical center, within same h	nealth system \Box Medical center, contracted locally
Commercial referral laboratory	Other (specify):
*2. Indicate whether your facility screens new admissions (MDROs): (check all that apply)	for any of the following multidrug-resistant organisms
\Box We do not screen new admissions for MDROs	
Methicillin-resistant Staphylococcus aureus (MRS	SA)
If checked, indicate the specimen types sent for	
\Box Nasal swabs \Box Wound swabs	□ Sputum □ Other skin site
□ Vancomycin-resistant <i>Enterococcus</i> (VRE)	
If checked, indicate the specimen types sent for	screening: (check all that apply)
□ Rectal swabs □ Wound swabs	
 Multidrug-resistant gram-negative rods (includes resistant Acinetobacter, etc.) If checked, indicate the specimen types sent for 	carbapenemase resistant Enterobacteriaceae; multidrug- screening: (check all that apply)
\Box Rectal swabs \Box Wound swabs	□ Sputum □ Urine
*3. What is the primary testing method for <i>C. difficile</i> used laboratory where your facility's testing is performed?	
Enzyme immunoassay (EIA) for toxin	\Box GDH plus NAAT (2-step algorithm)
Cell cytotoxicity neutralization assay	□ GDH plus EIA for toxin, followed by NAAT for discrepant results
Nucleic acid amplification test (NAAT) (e.g., PCR, LAMP)	Toxigenic culture (C. difficile culture followed by detection of toxins)
Glutamate dehydrogenase (GDH) antigen plus EIA for toxin (2-step algorithm)	Other (specify):
("Other" should not be used to name specific laboratories, refere methods can be categorized accurately by selecting from the op Instructions for this form, or conduct a search for further guidanc	tions provided. Please ask your laboratory, refer to the Tables of
*4. Does your laboratory provide a report summarizing the identified in cultures sent from your facility (often called)	e percent of antibiotic resistance seen in common organisms d an antibiogram)?
□ Yes □ No	
If Yes, how often is this summary report or antibiogra	m provided to your facility? (check one)
□ Once a year □ Every 2 years	□ Other (specify):
	Continued >>



Infection Prevention and Control Practices	
*5. Total staff hours per week dedicated to infection prevention and control activity in facility:	
a. Total hours per week performing surveillance:	
b. Total hours per week for infection prevention and control activities other than surveillanc	:e:
*6. Does the facility routinely require use of gowns/gloves for care of residents infected or cold (check one)	nized with MRSA?
\square Yes, all infected and colonized residents	
\Box Yes, only residents with active infection	
Yes, only those with certain characteristics that make them high-risk for transmission (presence of an indwelling device)	(e.g., wounds, diarrhea
 Does the facility routinely require use of gowns/gloves for care of residents infected or cold (check one) 	onized with VRE?
\Box Yes, all infected and colonized residents	
\Box Yes, only residents with active infection	
 Yes, only those with certain characteristics that make them high-risk for transmission (presence of an indwelling device) No 	(e.g., wounds, diarrhea
 *8. Does the facility routinely require use of gowns/gloves for care of residents infected or cold (check one) 	Divid with CRE?
\square Yes, all infected and colonized residents	
\Box Yes, only all residents with active infection	
 Yes, only those with certain characteristics that make them high-risk for transmission (presence of an indwelling device) No 	(e.g., wounds, diarrhea
*9. Does the facility routinely require use of gowns/gloves for care of residents infected or cold producing or extended spectrum cephalosporin resistant Enterobacteriaceae in contact presistant enterobacteriaceae in contacteriaceae in contacteria	
\Box Yes, all infected and colonized residents	
\Box Yes, only residents with active infection	
Yes, only those with certain characteristics that make them high-risk for transmission (presence of an indwelling device)	(e.g., wounds, diarrhea
□No	
*10. When a resident colonized or infected with an MDRO is transferred to another facility, does your facility communicate the resident's MDRO status to the receiving facility at the time of transfer?	□ Yes □ Ne
	Continued 3



Ña Sa

tiona	Long Term Care Facility Component—Annual Facility Survey					
fet	Infection Prevention and Control Practices (continued)					
	*11. Among residents with an MDRO admitted to your facility from other healthcare facilities, what percentage of the time does your facility receive information from the transferring facility about resident's MDRO status?		%			
Ī	Antibiotic Stewardship Practices					
	*12. Is there a leader responsible for the impact of activities to improve use of antibiotics at your facility?		🗆 No			
	If Yes, what is the position of this leader?					
	Medical director Director of Nursing					
	Consultant Pharmacist Other (please specify):					
	*13. Does your facility have a policy that requires prescribers to document an indication for all antibiotics in the medical record or during order entry?		🗌 No			
	If Yes, has adherence to the policy to document an indication been monitored?	□ Yes	🗌 No			
	*14. Does your facility provide facility-specific treatment recommendations, based on national guidelines and local susceptibility, to assist with antibiotic decision making for common clinical conditions?	□ Yes	□ No			
	If Yes, has adherence to facility-specific treatment recommendations been monitored?	□ Yes	🗌 No			
	*15. Is there a formal procedure for performing a follow-up assessment 2-3 days after a new antibiotic start to determine whether the antibiotic is still indicated and appropriate (e.g. antibiotic time out)?	□ Yes	🗆 No			
	*16. Does a physician, nurse, or pharmacist review courses of therapy for specified antibiotic agents and communicate results with prescribers (i.e., audit with feedback) at your facility?		🗆 No			
	*17. Does the pharmacy service provide a monthly report of antibiotic use (e.g., new orders, number of days of antibiotic treatment) for the facility?		□ No			
	*18. Has your facility provided education to clinicians and other relevant staff on improving antibiotic use in the past 12 months?		□ No			
	Electronic Health Record Utilization					
	*19. Indicate whether any of the following are available in an <u>electronic health record</u> (check all tha	at apply):				
	Microbiology lab culture and antimicrobial susceptibility results Microbiology lab culture and antimicrobial					
	□ Medication administration record □ Resident vital signs					
	□ Resident admission notes □ Resident progress notes					
	□ Resident transfer or discharge notes □ None of the above					